Predictive Correlation Between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): Implications for Calculating a Derived SHIM for Clinical Use
Cornell University, Итак, New York, United States Journal of Sexual Medicine
(Impact Factor: 3.15).
09/2007; 4(5):1336-44. DOI: 10.1111/j.1743-6109.2007.00576.x
Validated questionnaires are used to assess postoperative continence, sexual function, and other quality-of-life issues after radical prostatectomy. The International Index of Erectile Function (IIEF) is one such well-tested inventory that is routinely used. However, some centers use the Sexual Health Inventory for Men (SHIM) or the IIEF-6 to record erectile function, and comparison between the three can be difficult.
To define if there was a predictive correlation between IIEF (or IIEF-6) and SHIM, and to explore a strategy for the use of an abbreviated and rapid functional assessment of erectile function in patients.
Preoperative and postoperative IIEF questionnaires from the robotic prostatectomy program at our institution were included in the study. The total IIEF, IIEF-6, and SHIM scores were calculated and correlations between the three were sought. We also looked at the feasibility of using only two questions from the IIEF with an aim of calculating both the SHIM and IIEF scores.
The power to differentiate between patients with SHIM >or=22 from those with SHIM <or=21 for (i) the ratio allowing direct conversion of IIEF (or IIEF-6) to SHIM; and (ii) a two-question-based recalculation of SHIM.
Two hundred seventy-five questionnaires were available for review. If the total IIEF score is known, the IIEF-derived SHIM score can be calculated by dividing the total IIEF score by a factor of 2.8 and then rounding off to a whole number. Furthermore, we have shown that an abbreviated questionnaire using Q5 and Q15 of the IIEF can be used to calculate the SHIM scores (two-question-SHIM).
We described an easy way to calculate the SHIM score when the IIEF (or IIEF-6) score alone is known. The two-question model can be used for a rapid assessment of the patients' sexual function.
Available from: Ahmed Mahmoud Al Adl
- "To evaluate their baseline ED, the Sexual Health Inventory for Men (SHIM-5) questionnaire was used at the baseline visit and after 2 months, with threshold scores set as no ED > 22, mild 17–21, moderate 8–16, and severe ED < 7  . The questions were preceded by 'over the past 4 weeks' and not 'over the past 6 months' as in the original version. "
[Show abstract] [Hide abstract]
To investigate the effect of chronic use of sildenafil and intracavernous injection (ICI) with trimix in men not responding to on-demand monotherapy with sildenafil or ICI with prostaglandin-E1 (PGE1).
Patients and methods
The study included 40 patients with erectile dysfunction (ED), with a mean (SD) age of 50.7 (11.3) years and unresponsive to on-demand sildenafil or ICI with PGE1 as monotherapy. They were assessed using the Sexual Health in Men (SHIM)-5 score for ED severity, penile colour Doppler ultrasonography (CDUS) for peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistance index (RI) with an ICI test using 0.25 mL of trimix of papaverine, PGE1 and phentolamine. Testosterone, prolactin and cholesterol levels were assessed. Patients received 25 mg sildenafil daily for 8 weeks, combined with twice weekly ICI with 0.25 mL of trimix. After treatment, the Erection Hardness Score (EHS), penile CDUS with ICI and ED Inventory of Treatment Satisfaction were assessed.
The mean (SD) SHIM-5 score before treatment was 8.3 (0.5) in 15 of the 40 men and 6.3 (0.4) in 25. Penile haemodynamics were normal in five (13%), showed arterial insufficiency in five (13%), venous occlusive disease in 26 (65%) and mixed vascular in four (10%). There was an improved SHIM-5 score in 28 (70%) patients, as shown by their haemodynamic values, duration of erection and EHS with therapy, and 66% satisfaction with treatment. Adverse effects (penile pain, headache, facial flushing, dyspepsia, nasal congestion, dizziness) were reported in 17 patients (43%).
Chronic use of trimix plus daily low-dose sildenafil improved penile haemodynamics in these patients with ED not responding to on-demand phosphodiesterase-5 inhibitors or ICI with PGE1 monotherapy.
Arab Journal of Urology 06/2011; Volume 9, 153–158(2):153-158. DOI:10.1016/j.aju.2011.06.008
[Show abstract] [Hide abstract]
ABSTRACT: IntroductionRace and ethnicity are important factors in health-related quality of life (QOL) because of racial differences in preferences
for, and trust in, health systems. Such factors are likely to affect QOL and patient satisfaction with care.
ResultsUsing a self-reported questionnaire, Japanese men with prostate cancer reported lower sexual function scores at baseline.
In detail, Japanese men were more likely than American men to report poor sexual desire, poor erection ability, poor overall
ability to function sexually, poor ability to attain orgasm, poor quality of erections, infrequency of erections, infrequency
of morning erections, and intercourse in the previous 4weeks. However, Japanese men were less likely than American men to
be concerned about their sexual function. Twoyears after surgery, American patients were more likely than Japanese patients
to regain their baseline sexual function. The use of phosphodiesterase-5 (PDE-5) inhibitors has been widely publicized as
the solution to erectile dysfunction after prostate cancer treatment. Although PDE-5 inhibitors have been available in Japan
since 1999, it is striking that Japanese men with localized prostate cancer are much less likely (only 10%) to use PDE-5 inhibitors
than American men.
ConclusionJapanese patients with localized prostate cancer report worse sexual function but are less concerned about their reduced function.
In the absence of a biological explanation for such differences, however, we suspect that cultural differences may explain
the differences between QOL survey results from Japanese or American men with prostate cancer.
KeywordsProstatic neoplasms–Quality of life–Erectile dysfunction–Cross-cultural comparative study
Reproductive Medicine and Biology 06/2011; 10(2):59-68. DOI:10.1007/s12522-011-0076-7
[Show abstract] [Hide abstract]
ABSTRACT: Educational status has been investigated rarely as a potential factor affecting the behavior of patients with new onset erectile dysfunction (ED) toward seeking first medical help and subsequent compliance with prescribed phosphodiesterase type 5 inhibitor (PDE5) therapy.
To test whether the educational status of patients with new onset ED and naïve to PDE5 therapy may have a significant impact on the delay before seeking first medical help (DSH) and compliance with the suggested PDE5.
Assessing DSH and compliance with PDE5 in new onset ED patients according to their educational status by means of detailed logistic regression analyses.
Data from 302 consecutive patients with new onset ED and naïve to PDE5s were comprehensively analyzed. Patients were segregated according to their educational status into low (elementary and/or secondary school education) and high (high school and/or university degrees) educational levels. Complete data were available for 231 assessable patients. Univariate (UVA) and multivariate (MVA) logistic regression analyses addressed the association between educational status and DSH after adjusting for age, relationship status, and Sexual Health Inventory for Men score. Likewise, UVA and MVA were performed to test the association between educational status and patient compliance with PDE5 at the 9-month median follow-up.
Median DSH was 24 months (range 1-350; mean 38.1 +/- 42.8). The lower the educational status, the shorter the DSH (P = 0.03). In contrast, a significantly (P < 0.0001) greater proportion of patients with a higher educational status showed compliance with the suggested PDE5 at the 9-month follow-up. Overall, educational status was not an independent predictor of either DSH or patient compliance with PDE5 therapy.
After adjusting for other variables, our findings suggest that in new onset ED patients, educational status does not independently affect the DSH and patient compliance with PDE5 therapy.
Journal of Sexual Medicine 04/2008; 5(8):1941-8. DOI:10.1111/j.1743-6109.2008.00810.x · 3.15 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.